Potent PDE9 inhibitor (IC50
= 22 nM). Also exhibits a high affinity for cGMP (Km
= ~170 nM). Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman et al.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Lee et al.
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey et al.